Previous studies have reported that FXYD-domain-containing ion-transport regulator 5 (FXYD5) enhances the resistance of HCC cells to sorafenib by activating the AKT/mTOR-signaling pathway [44]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.